We submit the unaudited financial results for the quarter ended 30th June, 2025 pursuant to Regulation 33 of SEBI (LODR), 2015.
Awaiting price reaction for this filing.
Sarda Proteins Ltd filed its unaudited Q1 FY26 results (quarter ended 30 June 2025) along with a clean limited review report from S K Agarwal & Associates. Revenue from operations fell sharply to Rs. 1,095.46 lakhs from Rs. 2,419.10 lakhs in the same quarter last year, a drop of roughly 55%. Total expenses stood at Rs. 1,144.88 lakhs versus Rs. 2,417.15 lakhs earlier. The company swung from a small profit before tax of Rs. 2.02 lakhs in Q1 FY25 to a loss before tax of Rs. 49.34 lakhs in Q1 FY26. Profit after tax was a loss of Rs. 49.34 lakhs (vs. Rs. 0.51 lakhs profit), translating to a basic EPS of Rs. (2.86) versus Rs. 0.03 earlier. The company operates in a single segment – renewable energy / solar cell products.
Negative for shareholders: revenue roughly halved year-on-year and the company slipped into a loss compared to a small profit last year, signalling weak demand or pricing pressure in its solar business in the current quarter.